2m 2m 2m 2m 2m 2m 2m
AVALO THERAP (AVTX)
NASDAQ
$13.90-$0.06 (-0.43%)
Price as of Jun 03, 2026 7:30 PM EDT- $838.4MMarket Cap
- 217.27%1-Year Change
- BiotechnologyIndustry
AVALO THERAP (AVTX)
$13.90-$0.06 (-0.43%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 441,000 -77.08% | 1.9M -89.34% | 18.1M +234.40% | |
Cost of Revenue | N/A N/A | N/A N/A | 1.3M -62.61% | 3.4M +130.32% | |
Gross Profit | 0 -100.00% | 441,000 -31.09% | 640,000 -95.62% | 14.6M +274.12% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | 10.3M N/A | N/A N/A | |
Research and Development Expense | -50.1M +104.95% | -24.4M +77.29% | -13.8M -55.97% | -31.3M -47.68% | |
Depreciation and Amortization Expense | 344,000 +103.55% | 169,000 +6.96% | 158,000 -4.82% | 166,000 -89.98% | |
Total Operating Expenses | 73.0M +5.85% | 69.0M +135.54% | 29.3M -47.24% | 55.5M -36.60% | |
Operating Profit | -72.9M +6.44% | -68.5M +150.49% | -27.4M -26.95% | -37.4M -54.42% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -3.4M -18.06% | -4.2M +74.40% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -3.4M -18.06% | -4.2M +74.40% | |
Total Nonoperating Income and Expense | -5.2M -115.43% | 33.5M +901.56% | -4.2M -0.26% | -4.2M +73.79% | |
Income before Taxes | -78.1M +123.03% | -35.0M +11.05% | -31.5M -24.26% | -41.6M -50.76% | |
Income Taxes | 165,000 +44.74% | 114,000 +714.29% | 14,000 -50.00% | 28,000 +114.29% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -78.3M +122.78% | -35.1M +11.37% | -31.5M -24.28% | -41.7M -50.63% | |
Net Income from Continuing Operations Applicable to Common | -78.1M +123.03% | -35.0M +11.05% | -31.5M -24.31% | -41.7M -50.61% | |
Basic EPS and Net Income | -5.84 -26.45% | -7.94 -93.04% | -114.00 +2,473.36% | -4.43 +433.73% | |
Diluted EPS and Net Income | -5.84 -72.07% | -20.91 -81.66% | -114.00 +2,473.36% | -4.43 +433.73% | |
Basic Weighted Average Shares | 13.4M +202.86% | 4.4M +1,493.70% | 277,727 -97.05% | 9.4M -90.58% | |
Diluted Weighted Average Shares | 13.4M +78.82% | 7.5M +2,599.19% | 277,727 -97.05% | 9.4M -90.58% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 15.9M -88.21% | 134.5M +1,714.51% | 7.4M -43.71% | 13.2M -75.87% | |
Short-Term Investments | 82.5M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 98.3M -26.91% | 134.5M +1,714.51% | 7.4M -43.71% | 13.2M -75.87% | |
Total Current Assets | 105.3M -24.19% | 138.9M +1,554.44% | 8.4M -48.86% | 16.4M -73.46% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 460,000 -61.95% | 1.2M -38.47% | 2.0M -18.50% | 2.4M -10.54% | |
Total Long-Term Assets | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Assets | 116.5M -22.74% | 150.7M +618.01% | 21.0M -37.08% | 33.4M -58.40% | |
Income Taxes Payable | 434,000 +60.74% | 270,000 +74.19% | 155,000 +9.93% | 141,000 +24.78% | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 5.9M N/A | |
Total Current Liabilities | 12.9M +85.92% | 7.0M +50.71% | 4.6M -79.12% | 22.1M +11.19% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 13.5M -58.93% | |
Total Long-Term Liabilities | 35,000 -90.00% | 350,000 -74.38% | 1.4M -20.16% | 1.7M -25.54% | |
Total Liabilities | 33.4M +88.75% | 17.7M +29.30% | 13.7M -69.09% | 44.3M -22.49% | |
Retained Earnings | -448.5M +21.14% | -370.3M +10.48% | -335.1M +10.31% | -303.8M +15.89% | |
Total Stockholders Equity | 83.0M -37.57% | 133.0M +1,721.36% | 7.3M +166.92% | -10.9M -147.29% | |
Total Shares Outstanding | 18.5M +76.78% | 10.5M +1,206.14% | 801,746 -91.50% | 9.4M -91.64% | |
Cash Flow | |||||
Cash from Operating Activities | -51.5M +4.90% | -49.1M +59.90% | -30.7M +14.69% | -26.8M -62.27% | |
Capital Expenditures | 7.5M N/A | 0 -100.00% | 158,000 +66.32% | 95,000 -15.93% | |
Cash from Investing Activities | -81.7M -23,055.06% | 356,000 +367.67% | -133,000 +40.00% | -95,000 -15.93% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 14.6M -91.70% | 175.8M +602.22% | 25.0M +270.37% | -14.7M -113.77% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | 33.26% -58.92% | 80.98% +11.88% | |
Operating Margin | N/A N/A | -15,535.60% +992.85% | -1,421.57% +585.38% | -207.41% -86.37% | |
Return on Assets | -58.58% +43.18% | -40.91% -64.75% | -116.06% +58.21% | -73.35% -46.11% | |
Return on Equity | -72.43% +44.68% | -50.06% -102.87% | 1,747.11% +355.14% | -684.77% +93.33% | |
Revenue Growth | -100.00% +29.74% | -77.08% -13.73% | -89.34% -138.11% | 234.40% +1,307.25% | |
Current Ratio | 8.14 -59.23% | 19.96 +997.72% | 1.82 +144.90% | 0.74 -76.13% | |
Cash Ratio | 1.23 -93.66% | 19.33 +1,103.92% | 1.61 +169.59% | 0.60 -78.30% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.00 +100.00% | -1.78 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.00 -100.00% | 0.58 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow